42,100 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Bought by Kennondale Capital Management LLC

Kennondale Capital Management LLC bought a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 42,100 shares of the company's stock, valued at approximately $280,000. Kennondale Capital Management LLC owned approximately 0.08% of Stoke Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Net Worth Advisory Group purchased a new stake in Stoke Therapeutics in the 1st quarter valued at $138,000. GAMMA Investing LLC raised its holdings in shares of Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after acquiring an additional 5,084 shares in the last quarter. California State Teachers Retirement System raised its holdings in Stoke Therapeutics by 16.2% in the fourth quarter. California State Teachers Retirement System now owns 32,068 shares of the company's stock worth $354,000 after purchasing an additional 4,468 shares in the last quarter. Toronto Dominion Bank purchased a new stake in shares of Stoke Therapeutics during the fourth quarter valued at $35,001,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after purchasing an additional 52,813 shares during the period.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider directly owned 25,782 shares of the company's stock, valued at $258,593.46. This represents a 20.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 9.50% of the company's stock.

Stoke Therapeutics Stock Performance

STOK stock traded down $0.49 on Friday, reaching $13.03. The company had a trading volume of 341,733 shares, compared to its average volume of 792,768. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $16.15. The company's fifty day moving average is $11.30 and its 200 day moving average is $9.69. The company has a market cap of $711.13 million, a P/E ratio of 16.49 and a beta of 1.14.

Wall Street Analyst Weigh In

A number of analysts have issued reports on STOK shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. HC Wainwright cut their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Jefferies Financial Group began coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a "buy" rating and a $30.00 price target on the stock. Finally, Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $25.80.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.